Actively Recruiting
Phase II Study of Ruxolitinib Treatment for Adults With T-Cell Large Granular Lymphocytic Leukemia
Led by Jonathan Brammer · Updated on 2026-02-10
30
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the use of ruxolitinib for patients with T-cell large granular lymphocyte leukemia T-LGLL, a type of cancer affecting certain white blood cells. This phase II trial aims to determine how well ruxolitinib can shrink tumors and improve blood cell counts compared to historical results. The study also looks at safety, quality of life, and molecular changes over time in people living with this leukemia. Participants take ruxolitinib orally twice a day in 28-day cycles for up to 12 months, as long as the disease does not worsen and side effects remain acceptable. Those who respond to the treatment may continue for another 12 months, with a maximum treatment period of 24 months. Blood samples are collected throughout to monitor the disease and treatment effects. During the study, participants will have regular assessments including blood tests, quality of life questionnaires, and monitoring for side effects. The main goal is to measure the overall response rate within 12 months. Secondary goals include evaluating survival without leukemia progression and changes in quality of life over the same period. Participants are followed closely to track their health and treatment outcomes.
CONDITIONS
Brief Title
Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia
Research Team
T
The Ohio State University Comprehensive Cancer Center
L
Lily Yang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
